A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan
NCT ID: NCT01197014
Last Updated: 2011-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
72 participants
INTERVENTIONAL
2010-09-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- A single center, open, randomized, single dose, two-period, two-treatment, two-sequence, crossover study
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan
NCT01197001
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers
NCT01648231
Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions
NCT00602017
Bioequivalence Study of Amlodipine and Norvasc Under Fasting and FED Conditions in Chinese Healthy Volunteers
NCT02974439
Bioequivalency Study of Amlodipine Tablets Under Fed Conditions
NCT00601302
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\- To assess the bioequivalence of combination oral formulation of amlodipine/losartan versus two co-administered products containing amlodipine and losartan
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Amlodipine plus Losartan
Amlodipine plus Losartan
Amlodipine/Losartan high dose
Amlodipine, Losartan
Amlodipine, Losartan
Amlodipine, Losartan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amlodipine plus Losartan
Amlodipine/Losartan high dose
Amlodipine, Losartan
Amlodipine, Losartan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy Caucasian volunteers
* Non smokers or mild smokers
Exclusion Criteria
* Participation in another clinical trial within 60 days prior to Period 1
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hanmi Pharmaceutical Company Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hanmi Pharmaceutical Company Limited.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CEPHA s.r.o.
Pilsen, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-ALOS-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.